Pacer Advisors
BCRX icon

Pacer Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Pacer Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44K Sell
4,436
-1,558,604
-100% -$14.1M ﹤0.01% 2065
2026
Q1 		$14.9M Buy
+1,563,040
New +$12.1M 0.04% 368
2024
Q3 		– Sell
-2,649
Closed -$16.4K – 2578
2024
Q2 		$16.4K Sell
2,649
-4,657
-64% -$25.7K ﹤0.01% 3465
2024
Q1 		$37.1K Buy
+7,306
New +$41.1K ﹤0.01% 3291
2021
Q2 		– Sell
-6,177
Closed -$63K – 1424
2021
Q1 		$63K Sell
6,177
-9,768
-61% -$101K ﹤0.01% 1408
2020
Q4 		$119K Sell
15,945
-8,558
-35% -$44.1K ﹤0.01% 1336
2020
Q3 		$84K Buy
+24,503
New +$105K ﹤0.01% 1274
2018
Q4 		– Sell
-7,158
Closed -$55K – 581
2018
Q3 		$55K Buy
+7,158
New +$48.1K ﹤0.01% 1139
2018
Q1 		– Sell
-2,100
Closed -$10K – 1045
2017
Q4 		$10K Buy
+2,100
New +$10.2K ﹤0.01% 1142

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Pacer Advisors's BCRX Position: Q2 2026 in Review

Pacer Advisors reduced its BioCryst Pharmaceuticals (BCRX) stake by 100% in Q2 2026, selling an estimated $14.1M and leaving 4,436 shares worth $44K. The position accounts for ﹤0.01% of the portfolio, ranked #2065.

Pacer Advisors first reported a position in BCRX in Q4 2017 and has held it in 9 quarters since. The position peaked at $14.9M in Q1 2026. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Pacer Advisors held 4,436 shares of BioCryst Pharmaceuticals worth $44K as of Q2 2026.
  • Pacer Advisors sold 1,558,604 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $14.1M.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2065 holding.
  • Pacer Advisors first reported a position in BioCryst Pharmaceuticals in Q4 2017 and has held it in 9 quarters since.
  • Pacer Advisors's BioCryst Pharmaceuticals position peaked at $14.9M in Q1 2026.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.